Semaglutide is the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent in most markets through 2031, but the Indian patent expired in March 2026 and a wave of generics from Biocon, Dr. Reddy's, and others followed within weeks.
The cardiovascular and renal evidence has expanded fastest. SELECT showed a 20% reduction in MACE for non-diabetic adults with obesity. The REMODEL trial (presented at the World Congress of Nephrology 2026) showed direct kidney protection independent of weight loss. Cell Metabolism work from Sinai Health pinned MASH reversal to liver sinusoidal endothelial cells, not weight loss or appetite. JAMA published a 90,000-patient HFpEF analysis showing a 42% reduction in heart-failure hospitalization or all-cause mortality.
The compounding story keeps moving in parallel. The FDA proposed excluding semaglutide from the 503B bulks list on April 30, 2026, with public comment open through June 29. Tirzepatide and liraglutide were folded into the same proposal.
Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.
An ECO 2026 analysis covered May 18 by ScienceDaily examined 89,718 patients starting GLP-1 therapy — 75.6% semaglutide, 17.5% tirzepatide, 6.9% liraglutide — and stratified BMI change at year one. In the first year, 27% reduced BMI by less than 5%, 22.4% by 5-10%, 14.1% by 10-15%, and 15.8% by ≥15%, while 20.8% actually gained weight. Greater weight loss correlated with larger reductions in obesity-related risk endpoints; patients who gained weight after starting treatment faced worse health outcomes than untreated comparators in several measures.
The EASO 2026 Nature Medicine framework published May 14, presented at ECO 2026 — formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications with differentiated complication-specific recommendations — has generated initial reception coverage. The Endocrine Society and American Diabetes Association haven't yet issued formal endorsement or counter-response statements as of May 16, though informal commentary from US endocrinologists has been broadly favorable. The framework's main US-specific gap is its silence on cost and insurance access — the algorithm assumes prescribers can choose between semaglutide and tirzepatide based on clinical indication, but US patients without diabetes face the Medicare Part D weight-loss-only exclusion. The Medicare GLP-1 Bridge launching July 1, 2026 partly addresses that gap; broader integration awaits CMS rulemaking. ADA 2026 Scientific Sessions in New Orleans June 5-8 will be the next inflection point for guideline alignment between US and EASO positions.
The Lancet's 'Making Treatment for Obesity More Equitable' editorial (March 2026) and an accompanying medRxiv preprint (Hill et al., March 4, 2026) synthesized 2024-2025 active pharmaceutical ingredient shipment data to estimate generic semaglutide production costs at $28-140/person-year for injectable formulations and $186-380/person-year for oral formulations. By the end of 2026, generic injectable semaglutide could be available in 160 countries covering 69% of global T2DM and 84% of clinical obesity. The 10 countries where Novo Nordisk's 2026 patents expired represent 44% of the global population and 48% of the global obesity burden — including Brazil, Canada, China, India, and Turkey. The constraint isn't manufacturing economics; it's device-patent thickets (57% of analyzed semaglutide patents are device patents) and policy coordination (pooled procurement, voluntary licensing, tiered pricing).
The European Association for the Study of Obesity published an updated pharmacological framework in Nature Medicine, presented at ECO 2026 in Istanbul on Thursday May 14. Semaglutide and tirzepatide are recommended as first-line treatment for obesity across most complications. Tirzepatide is preferred for obstructive sleep apnea and MASH; semaglutide is preferred for knee osteoarthritis and established cardiovascular disease — and is the only agent with current evidence supporting MASH-fibrosis improvement. The framework integrated evidence through November 21, 2025 from 62 randomized controlled trials. The algorithm uses obesity-related complication presence as the primary treatment-selection factor and provides the first major obesity-society guideline to formally privilege incretin-based therapy across the indication mix.
Prof. Jens-Christian Holm and colleagues at the Children's Obesity Clinic (European Centre for Obesity Management at Holbæk Hospital) presented RESETTLE at ECO 2026 on May 13. The randomized trial enrolled young adults aged 18-28 who remained severely obese despite at least one year of hospital-based non-pharmacological treatment in childhood. After 68 weeks of once-weekly semaglutide 2.4 mg vs placebo, the treatment arm achieved 19% mean BMI reduction (22.3 kg average weight loss). Total fat mass, abdominal fat, and liver fat all improved substantially vs placebo. The data fills a clinical gap — most semaglutide weight-loss trials excluded young adults coming out of structured pediatric obesity programs, leaving prescribers without evidence for one of the most underserved cohorts.
Prof. Luca Busetto (University of Padova) and colleagues will present at ECO 2026 a pooled subgroup analysis of 358 adults aged 65 and older (mean age 69, 72% women) drawn from STEP 1, 3, 4, 5, 8, and 9 — 248 received semaglutide 2.4 mg, 110 placebo. The semaglutide arm lost 15.4% body weight on average vs 5.1% on placebo; 46.8% of semaglutide users hit ≥15% weight loss vs 6.4% on placebo, and 28.6% reached ≥20% vs 2.7%. Waist circumference fell 14.3 cm vs 6.0 cm. 27% on semaglutide reached a healthy BMI (<27) vs 5.5%. Serious adverse events occurred in 19.0% on semaglutide vs 12.7% on placebo. The analysis complements Lilly's ECO 2026 orforglipron 65+ subgroup analysis from ATTAIN-1 and ATTAIN-2 — both filling the geriatric data gap for the first generation of mainstream obesity drugs.
Rice University assistant professor Erin Standen and colleagues at the Mayo Clinic (Sean Phelan) and UCLA (Janet Tomiyama) published in the International Journal of Obesity on May 5 a study finding that adults who lose weight via GLP-1 receptor agonists like Ozempic and Wegovy face more judgment than those who lose weight through diet and exercise — or who do not lose weight at all. The stigma framing centers on 'easy way out' perceptions and intensifies if the patient later regains weight. The work joins the broader social-context literature shaping the GLP-1 era — including the Ozempic Face plastic-surgery surge, GLP-1-related shame disclosures, and patient-reported drift away from disclosing medication use to friends and family.
A Frontiers in Endocrinology multicenter retrospective cohort study (2026) reports real-world safety and effectiveness of semaglutide in patients with type 2 diabetes and end-stage renal disease — the population systematically excluded from FLOW (which capped at eGFR ≥ 25) and the SELECT pre-specified kidney composite analysis. ESRD patients comprise roughly 1% of the diabetic population but 7% of US healthcare spending; their cardiovascular event rates are among the highest documented. The cohort fills a clinical gap: prescribers managing dialysis-dependent patients have had to extrapolate from outcome trials that explicitly excluded the population. Work joins the SOUL oral-semaglutide CKD analysis as the fastest-growing GLP-1 evidence stream beyond obesity and T2D.
Novo Nordisk's Q1 print clarified that Wegovy HD (semaglutide 7.2 mg injection) — approved by the FDA in March and launched in the US on April 7 — is contributing to the premium-tier injectable mix alongside the standard 2.4 mg dose. The STEP UP trial showed 21% mean weight loss at 72 weeks if all patients stayed on treatment (19% regardless), with 89% on 7.2 mg achieving ≥5% body-weight reduction versus 38% with placebo. The label requires four-plus weeks of tolerability on semaglutide 2.4 mg before stepping up. NovoCare prices the 7.2 mg dose at $399/month self-pay and as low as $25 for many commercially insured patients via the savings offer. Dysesthesia at 22% on 7.2 mg vs. 6% on 2.4 mg and 0.3% on placebo is the only meaningful safety signal beyond the broader GLP-1 class.
Novo Nordisk confirmed in its Q1 2026 commentary that a higher-dose CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) Phase 3 trial will start in the second half of 2026, in response to the February 23 readout where the lower-dose 2.4/2.4 mg arm achieved 23% mean weight loss vs. 25.5% on tirzepatide 15 mg over 84 weeks — failing the non-inferiority primary endpoint. The original CagriSema FDA filing is already submitted with a decision expected in late 2026; the higher-dose program is meant to position Novo for a more competitive head-to-head against tirzepatide before the retatrutide TRIUMPH readouts arrive. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
A living systematic review presented at the American Academy of Neurology 2026 Annual Meeting integrating Phase 2/3 trials and real-world data from 2+ million individuals with diabetes found GLP-1 receptor agonist use was associated with a 20-35% lower incidence of dementia versus DPP-4 or SGLT2 inhibitors. Effect was strongest for semaglutide, despite the EVOKE Phase 3 Alzheimer's trial missing its cognitive endpoint.
The first definitive Phase 3B head-to-head trial of Lilly's tirzepatide versus Novo Nordisk's semaglutide in 750 patients with obesity over 72 weeks showed tirzepatide produced 21.6% mean weight loss vs semaglutide's 15.4%. 36.2% of tirzepatide patients achieved ≥25% weight loss vs 19.4% on semaglutide. Results published April 20 give Lilly a clear comparative data point in the GLP-1 market share battle.
A University of Colorado Anschutz-led secret shopper study presented at Obesity Medicine Association 2026 surveyed 75 weight-loss clinics and medspas across two US states. 69 of 74 still offered compounded semaglutide and 65 of 74 offered compounded tirzepatide despite FDA resolving the name-brand shortages. Four source facilities had received FDA warnings or state licensing discipline since 2023 — three related to sterile compounding. Many clinics report using 'additive' formulations to skirt compounding restrictions.
Researchers at Toronto's Sinai Health published in Cell Metabolism that semaglutide acts directly on liver sinusoidal endothelial cells (LSECs) to reverse MASH independently of weight loss. Although LSECs account for only ~3% of liver cell volume, they are the key driver of hepatoprotection. Semaglutide reversed MASH in mice lacking brain appetite receptors, while mice lacking LSEC receptors saw no liver improvement despite losing 20% body weight.
A Cell Reports Medicine study presenting four preclinical experiments and a proof-of-concept clinical trial reports that GLP-1 medicines predominantly reduce body fat alongside a small but significant decrease in lean body mass in obese mice and humans. Among lean tissues, loss of liver mass exceeds change in muscle mass, and while absolute muscle mass and strength decrease, relative muscle mass and strength improve — translating into better running performance in mice.